A jury found that Tagrisso, an AstraZeneca lung cancer drug, violated Pfizer’s Wyeth unit’s patent rights under two patents. Pfizer claimed Tagrisso’s use of kinase inhibitors for cancer treatment infringed on its patent for Nerlynx, a breast cancer drug. AstraZeneca refuted the allegations and challenged the validity of the patents.
The U.S. District Court in Delaware ruled in favor of Pfizer; however, the case is set to continue in a separate bench trial in June to address AstraZeneca’s remaining defenses. The trial could overturn the current verdict.
AstraZeneca’s spokesperson told the news outlet that the company is disappointed with the verdict but is “confident in our intellectual property position in relation to Tagrisso” and intends to “vigorously defend” its rights.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.